Skip to Navigation Skip to Search Skip to Content
Search All Centers

ASCO 2018: A Patient Advocate's Perspective on Access to Testing, Treatment and Meaningful Data

Read Transcript Download/Print Transcript

Published on June 7, 2018

As technology continues to advance, so does the demand for chronic myeloid leukemia (CML) patients to access services like genetic testing to stay informed about the characteristics of their condition. What are the barriers to access? Can they also prevent patients from receiving the most effective treatment? On location at the 2018 American Society of Clinical Oncology (ASCO) meeting in Chicago, Jan Geissler, a 17-year CML survivor and director at the European Patients Academy on Therapeutic Innovation, gives a global perspective on the need for genetic testing, potential obstacles preventing patients from getting optimal care, and how data and education can help increase access to innovative treatments. 

 

Featuring

You might also like

Transcript | ASCO 2018: A Patient Advocate’s Perspective on Access to Testing, Treatment and Meaningful Data

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:         

What I was saying is that of course the patients have a lot of hope in genomic testing and testing in general but especially in, let's say, treating patients with the right treatment at the right time.  Make sure we don't overtreat patients.  Make sure that we are treated according to risk ratification, and making sure that we detect progress and whatever early to actually catch patients when they really need therapy. 

And of course there are—I mean, we see issues around access, access to testing, access to diagnostics because what happens with patients who cannot access treatment because they cannot access…

There are so many issues, especially with genomic data about the identification, about patient-relevant outcomes and so on.  And we as patient organizations engage in projects like that to contribute to research and make sure that patients actually join that and that research does meaningful things. 

I just want to thank you for what you're doing.  And I want to give you a hug, all right?  And good health, okay?

Knowledge can be the best medicine of all, and working together can make a difference.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.